Abstract
Manganese-based contrast agents (MnCAs) have emerged as suitable alternatives to gadolinium-based contrast agents (GdCAs). However, due to their kinetic lability and laborious synthetic procedures, only a few MnCAs have found clinical MRI application. In this work, we have employed a highly innovative single-pot template synthetic strategy to develop a MnCA, MnL Me, and studied the most important physicochemical properties in vitro. MnL Me displays optimized r 1 relaxivities at both medium (20 and 64 MHz) and high magnetic fields (300 and 400 MHz) and an enhanced r 1 b=21.1 mM −1 s −1 (20 MHz, 298 K, pH 7.4) upon binding to BSA (K a=4.2×10 3 M −1). In vivo studies show that MnL Me is cleared intact into the bladder through renal excretion and has a prolonged blood half-life compared to the commercial GdCA Magnevist. MnL Me shows great promise as a novel MRI contrast agent.
Original language | English |
---|---|
Pages (from-to) | 10736-10744 |
Number of pages | 9 |
Journal | Angewandte Chemie-International Edition |
Volume | 60 |
Issue number | 19 |
Early online date | 24 Feb 2021 |
DOIs | |
Publication status | Published - 3 May 2021 |
Keywords
- Mn-based contrast agents
- bishydrated MnCA
- blood pool agents
- in vivo MRI
- template synthesis